The Anglo-Swedish drugmaker remains one of the best bets in Big Pharma, and potential success in obesity isn’t priced in to the stock. The Anglo-Swedish drugmaker remains one of the best bets in Big Pharma, and potential success in obesity isn’t priced in to the stock.

​WSJ.com: Markets

WE WANT YOU!

are you a developer?

  • Proven International Track Record
  • Vertically Integrated Federal Funds
  • Vertically Integrated Tax Credits
  • Vertically Integrated Investors
  • Vertically Integrated Lenders
  • Vertically Integrated Contractors